Brevan Howard Capital Management LP Vaxcyte, Inc. Transaction History
Brevan Howard Capital Management LP
- $13.9 Billion
- Q4 2024
A detailed history of Brevan Howard Capital Management LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 4,393 shares of PCVX stock, worth $305,137. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,393
Previous 1,847
137.85%
Holding current value
$305,137
Previous $210,000
70.95%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PCVX
# of Institutions
350Shares Held
126MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$831 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$735 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$690 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$604 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$431 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.12B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...